We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 18, 2019

Comparing Cardiovascular Safety of Linagliptin With Other Glucose-Lowering Agents Using Claims Databases

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Cardiovascular Safety of Linagliptin Compared With Other Oral Glucose-Lowering Agents in Patients With Type 2 Diabetes: A Sequential Monitoring Programme in Routine Care
Diabetes Obes Metab 2019 Aug 01;21(8)1824-1836, E Patorno, C Gopalakrishnan, KG Brodovicz, A Meyers, DB Bartels, J Liu, M Kulldorff, S Schneeweiss

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading